Fusion Telecommunications Receives Two New Contract Awards

On November 30, Fusion Telecommunications (FSNN) announced that the company received two new contracts totaling $1.6 million. Fusion will use its advanced cloud voice and connectivity solutions to improve communications systems for a healthcare company as well as to a hospitality company. These new contracts mark the growth of Fusion’s services across the country in […]

Read more...

Emergent Biosolutions Receives FDA Approval for Vaccine Production

On November 20, Emergent Biosolutions Inc. (EBS) announced that the company received FDA approval on its supplemental Biologics License Application (sBLA) for the production of the ACAM2000 vaccine. This live vaccine for smallpox will be manufactured in the company’s new live viral manufacturing facility in Canton, Massachusetts. It is the only vaccine approved by the […]

Read more...

TheStreet Reports Improved Third Quarter Financial Performance and Share Repurchase Program

 TheStreet (TST) reported its third-quarter financial performance on November 13. The company had EPS of $0.01 compared to a loss of $0.03 during the same quarter last year. The Board of Directors also authorized a new share repurchase of up to 5 million common shares, which is the equivalent of 10% of current outstanding shares. […]

Read more...

JA Solar Enters Agreement to Go Private

On November 17, JA Solar Holdings Co., Ltd. (JASO) announced that the company entered into an agreement to go private. An investor group plans to purchase the company in an all-cash transaction valuing the company at $362.1 million. At the agreement’s effective time, all current shares of JASO will no longer exist. Shareholders will have […]

Read more...

Magal Awarded $3.5 Million Airport Security Contract

Magal Security Systems, Ltd. (MAGS) announced on November 10 that the company was awarded new contract to provide integrated security solutions at some of the world’s biggest airports. The contract totals around $3.5 million and includes international sites such as Barcelona airport and Indira Gandhi International airport in New Delhi. Magal is a leading international […]

Read more...

Collegium Receives FDA Approval for Xtampza® ER

On November 7, Collegium Pharamceutical, Inc. (COLL) announced FDA approval of its supplemental new drug application for Xtampza® ER. The drug is an abuse-deterrent, extended-release opiod, for severe pain management needing daily, long-term relief. This is an important advance considering the opiod addiction epidemic in the United States. Xtampza® ER is the only single-agent oxycodone with the […]

Read more...

Promising Clinical Trial Results From Flex Pharma

On November 6, Flex Pharma Inc. (FLKS) reported positive stage 2 clinical trial results for a new drug to treat cramps and spasticity associated with a variety of neurological disorders. Positive topline data for FLX-787 indicates that significant improvement of pain and cramping is possible for those suffering from multiple sclerosis (MS), amyotrophic lateral sclerosis […]

Read more...